undamentalytics Newsletter
Sign in

Bridgebio Pharma, Inc. income statement

In fiscal 2025, Bridgebio Pharma, Inc. reported revenue of $502m, up 126.3% on the year before, operating income of −$523m (a -104.2% margin) and net income of −$725m, or −$3.78 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue41870789222502946
Cost of revenue——33242154
Gross profit——67747218481892
Research and development210337451399456506452536
Selling, general and administrative94146192143151289531709
Operating income−266−474−577−512−607−593−523−364
Interest expense937478081915351
Income before tax289505—−485−653−542−733—
Income tax———0010—
Net income−261−449−563−481−643−536−725−566
Diluted EPS−$2.48−$3.80−$3.90−$3.26−$3.95−$2.88−$3.78−$2.90
Diluted shares (average)105m118m144m147m163m186m192m195m
EBITDA−265−473−571−505−601−587−518−359

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BBIO vs KNSABBIO vs BCRXBBIO vs IONSBBIO vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bridgebio Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bridgebio Pharma, Inc.